Intra-cellular Therapies, Inc. (ITCI) Tops Q2 EPS by 8c

Intra-cellular Therapies, Inc. (NASDAQ: ITCI) reported Q2 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $319.2 thousand versus the consensus estimate of $410 thousand.

For earnings history and earnings-related data on Intra-cellular Therapies, Inc. (ITCI) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Ecolab pops as Citi sees improving setup into Q2 earnings
• Odysight.AI Inc. (ODYS) PT Lowered to $6 at Benchmark